cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Crispr Therapeutics Ag
251 own
96 watching
Current Price
$65
$0.48
(0.74%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
5,103.31M
52-Week High
52-Week High
86.95
52-Week Low
52-Week Low
38.94
Average Volume
Average Volume
0.99M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
16.7148
iconMarket Capitalization5,103.31M
icon52-Week High86.95
icon52-Week Low38.94
iconAverage Volume0.99M
iconDividend Yield--
iconP/E Ratio16.7148
What does the Crispr Therapeutics Ag do?
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Read More
How much money does Crispr Therapeutics Ag make?
News & Events about Crispr Therapeutics Ag.
Accesswire
1month ago
BRENTWOOD, TN / ACCESSWIRE / April 11, 2023 / The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.A burgeoning sector within biotech is the cell...
Fool.com Headlines
1month ago
Vertex shares are on the rise.Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating billion-dollar revenue for years, thanks to its portfolio of cystic fibrosis (CF) drugs. In fact, Vertex is the global leader in CF treatment and likely to hang onto that position for quite some time. But soon, ...
Business Wire
2 months ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertexs...
Zolmax
2 months ago
CRISPR Therapeutics AG (NASDAQ:CRSP Get Rating) has been assigned a consensus rating of Hold from the twenty research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and nine have ...
Zolmax
3 months ago
CRISPR Therapeutics AG (NASDAQ:CRSP Get Rating) has been assigned an average rating of Hold from the seventeen brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and eight have ...
Frequently Asked Questions
Frequently Asked Questions
What is Crispr Therapeutics Ag share price today?
plus_minus_icon
Can Indians buy Crispr Therapeutics Ag shares?
plus_minus_icon
How can I buy Crispr Therapeutics Ag shares from India?
plus_minus_icon
Can Fractional shares of Crispr Therapeutics Ag be purchased?
plus_minus_icon
What are the documents required to start investing in Crispr Therapeutics Ag stocks?
plus_minus_icon
What is today’s traded volume of Crispr Therapeutics Ag?
plus_minus_icon
What is today’s market capitalisation of Crispr Therapeutics Ag?
plus_minus_icon
What is the 52-Week High and Low Range of Crispr Therapeutics Ag?
plus_minus_icon
What percentage is Crispr Therapeutics Ag down from its 52-Week High?
plus_minus_icon
What percentage is Crispr Therapeutics Ag up from its 52-Week Low?
plus_minus_icon
Current Price
$65
$0.48
(0.74%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00